Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world
View HTML
Toggle Summary Biocept Reports Second Quarter 2017 Financial Results
- Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition- Launch of "AND" campaign supports growth in test volume both sequentially and year-over-year- New provider agreements with both Scripps Health Plan and MediNcrease expand patient access to Biocept's proprietary liquid biopsy test platform- Secures $2.2 million investment from Ally Bridge LB Healthcare Master Fund- Evaluating strategic opportunities in China with Ally Bridge's Chinese affiliate- Company to host conference call at 4:30 p.m. Eastern time today
View HTML
Toggle Summary Biocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund
Biocept and Ally Bridge to evaluate strategic opportunities in China for the Company's liquid biopsy platform
View HTML
Toggle Summary Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform
Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer
View HTML
Toggle Summary Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017
SAN DIEGO , Aug. 3, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the
View HTML
Toggle Summary Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Biocept now offers 14 clinically actionable biomarker tests, including all validated biomarkers for breast cancer in NCCN Guidelines®
View HTML
Toggle Summary Biocept Added to the Russell Microcap Index
SAN DIEGO , June 26, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that is has been added to the Russell Microcap®
View HTML
Toggle Summary Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing
SAN DIEGO and ST. PETERSBURG, Fla. , June 21, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, and MediNcrease Health Plans, LLC
View HTML
Toggle Summary Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood
Company's intellectual property portfolio now features 20 issued patents protecting its proprietary liquid biopsy platform technology
View HTML
Toggle Summary Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign
Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsyClinical experience study evaluating 2,000 patient samples using Biocept's liquid biopsy tests shows detection of clinically actionable lung cancer mutations consistent with published prevalence rates"AND" marketing campaign highlights the benefits of using both liquid biopsy and tissue biopsy to improve the chances of rapidly identifying clinically actionable biomarkers in cancer patients
View HTML